Clinical Trial: The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Multi-center, Randomized, Double-blind, Cross-over, Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o. (300-1200 mg/Day) as Adjuvant Therapy for Impulsivity and

Brief Summary: Conduct disorder is a group of psychiatric symptoms that can include clinical characteristics of impulsivity and aggressive behavior. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of adolescents with conduct disorder.

Detailed Summary:
Sponsor: Novartis

Current Primary Outcome: Percentage reduction on Impulsivity Rating Scale (IRS)

Original Primary Outcome:

Current Secondary Outcome: Percent reduction in the Modified Overt Aggression Scale (MOAS)

Original Secondary Outcome:

Information By: Novartis

Dates:
Date Received: September 8, 2005
Date Started: April 2003
Date Completion:
Last Updated: November 22, 2011
Last Verified: November 2011